FDA, Sulodexide for long COVID, Brain Vessel Issues and Vaccines

Here’s what we know about COVID-19’s impact on the brainПодробнее

How Does the FDA Evaluate Vaccines?Подробнее

FDA adds warning of risk for rare neurological disorder to Johnson & Johnson coronavirus vaccineПодробнее

NIH launches long COVID trials to help millions of Americans with symptomsПодробнее

Why does the U.S. FDA approval of the COVID-19 vaccine matter?Подробнее

Neurological disorders & COVID-19 vaccinesПодробнее

Encephalitis After COVID-19 Vaccine Administration: PerspectivesПодробнее

FDA greenlights mixing and matching COVID vaccinesПодробнее

FDA says people need both doses of COVID-19 vaccinesПодробнее

Long hauler COVID success treatment story at Pain Specialists of BrightonПодробнее

FDA authorizes Pfizer's COVID-19 treatment pillПодробнее

FDA Finds Seizures Signal in 2-5 Year Old After COVID-19 mRNA VaccinesПодробнее

FDA Authorizes Pfizer for 6mo to Under 5, and Moderna COVID Vaccines for 6mo to 17Подробнее

FDA on COVID-19 Vaccines for Kids, Boosters, and TreatmentsПодробнее

Sulodexide - Glycosaminoglycan with antithrombotic propertiesПодробнее

Covid and the brain: A neurological health crisisПодробнее

STUDY: Fourth Dose Of Covid-19 Vaccine Is Ineffective For Young, Healthy, Boosted Adults - Need2KnowПодробнее

FDA Changes the Fall 2024 Updated Covid-19 Vaccine RecommendationПодробнее

Do COVID-19 Vaccines Cause Antibody-dependent Enhancement (ADE)?Подробнее